中药单体治疗糖尿病视网膜病变的研究进展
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金项目(No.U1932130); 陕西省科技厅重点研发一般项目(No.2021SF-303); 西安医学院配套基金项目(No.2018PT24); 西安医学院大学生创新创业训练计划项目(No.121521022)


Research progress of Chinese herb monomers in the treatment of diabetic retinopathy
Author:
Affiliation:

Fund Project:

National Natural Science Foundation of China(No.U1932130); The Key Program of Shaanxi Provincial Science and Technology Department(No.2021SF-303); The Talent Program of Xi'an Medical University(No.2018PT24); Innovation Program of University Students(No.121521022)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    糖尿病视网膜病变(DR)是一种常见的糖尿病慢性并发症,可导致视网膜中微血管的不可逆性损伤,是糖尿病患者首要致盲性眼病。DR的发病机制主要涉及氧化应激、炎症反应与新生血管形成等因素。临床上多以视网膜激光光凝术、玻璃体切割术或药物治疗为主。我国传统中药组方与中药单体在DR治疗,特别是视网膜保护方面具有独特功效,为DR治疗提供有益补充。本文综述了代表性中药组方与中药单体在DR治疗中的应用实践与作用机制,以期为DR的临床治疗与新药研发提供参考。

    Abstract:

    Diabetic retinopathy(DR)is a common chronic complication of diabetes mellitus, which cause irreversible damage of microvessels in the retina. DR is a leading blindness eye disease among diabetes mellitus. The pathogenesis of DR is mainly related to oxidative stress, inflammation and neovascularization. DR patients are treated with laser photocoagulation, vitrectomy and medicine in clinical trials. The traditional Chinese medicine and Chinese herb monomers have unique efficacy in the treatment of DR, especially in retinal protection, which provides valuable supplement. The paper summarized application practice and mechanism of representative Chinese herbal formulas and Chinese herb monomers in the treatment of DR, which would provide references for the clinical treatment and new drug development of DR.

    参考文献
    相似文献
    引证文献
引用本文

秦魏,郭蒙,李欣雨,等.中药单体治疗糖尿病视网膜病变的研究进展.国际眼科杂志, 2021,21(8):1373-1377.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-12-23
  • 最后修改日期:2021-07-08
  • 录用日期:
  • 在线发布日期: 2021-07-21
  • 出版日期:
文章二维码